EPHEDRINE SULFATE (ephedrine sulfate) by Dr. Reddy's Laboratories is α- and ß adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Approved for clinically important hypotension occurring in the setting of anesthesia. First approved in 2017.
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
Ephedrine sulfate is a sympathomimetic amine administered intravenously that acts as a direct and indirect α- and β-adrenergic receptor agonist. It increases arterial pressure, cardiac output, and peripheral resistance through both direct receptor activation and norepinephrine release from sympathetic neurons. It is used to treat hypotensive states requiring acute hemodynamic support.
Product is in peak commercial stage with moderate competitive pressure (30%), indicating stable market position and likely steady team staffing needs.
α- and ß adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic…
Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions
Worked on EPHEDRINE SULFATE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ephedrine sulfate offers exposure to hospital-based commercial strategy and acute care market dynamics. Career growth will depend on your ability to drive formulary adoption and compete against established vasopressor alternatives in critical care settings.